Press Releases
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024
ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025 NASHUA, N.H., November 26, 2024 — iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in clinically proven AI-powered cancer detection solutions, will showcase its groundbreaking…
iCAD Reports Financial Results for Third Quarter Ended September 30, 2024
NASHUA, N.H. – November 13, 2024 – iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months…
iCAD’s ProFound Detection Version 4.0 Gains FDA Clearance
NASHUA, N.H., November 12, 2024 — iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer detection solutions, announced today that its ProFound Detection Version 4.0 for Digital Breast Tomosynthesis (DBT) has received clearance from the U.S. Food and Drug Administration (FDA). This next-generation…
iCAD to Attend 15th Annual Craig-Hallum Alpha Select Conference
NASHUA, N.H. – Nov 6, 2024 – iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced that Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, will…
iCAD to Report Third Quarter 2024 Financial Results on November 13, 2024
NASHUA, N.H., November 5, 2024 — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the third quarter ended September 30, 2024, after market close and host a conference call at 4:30 PM Eastern Time on Wednesday,…
iCAD to Participate in the LD Micro Main Event XVII
NASHUA, N.H. – October 16, 2024 – iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the LD Micro Main Event XVII on October…
iCAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024
NASHUA, N.H., PARIS, FRANCE, October 3, 2024 – iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer detection solutions, today announced its participation in the 72nd edition of the Journées Francophones de Radiologie (JFR) 2024 Meeting, taking place from October 4-7 in Paris, France….
iCAD to Participate in the iAccess Alpha Buyside Best Ideas Fall Conference 2024
NASHUA, N.H. – September 11, 2024 – iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the iAccess Alpha Buyside Best Ideas Fall Conference…
iCAD Reports Financial Results for Second Quarter Ended June 30, 2024
NASHUA, N.H. – August 13, 2024 – iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and six months…
iCAD to Report Second Quarter 2024 Financial Results on August 13, 2024
NASHUA, N.H., August 6, 2024 — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the second quarter ended June 30, 2024 after market close and host a conference call at 4:30 PM Eastern Time on Tuesday,…